Information on COVID vaccines is moving fast. On May 27th, HHS Secretary Robert F. Kennedy Jr. announced that COVID vaccines will no longer be universally recommended for healthy children or healthy pregnant women. That's a big shift, and understandably, it's raised a lot of questions. We're going to cut through the noise and take a look at where things really stand, who's getting vaccinated, how current guidance is evolving, and what this means for both children and adults as we look ahead to the next respiratory season. Joining us to help sort it all out is Dr. John Schoen, Senior Clinical Manager of Drug Information at Vizient.

Guest speakers:

John Schoen, PharmD, BCPS

Senior Clinical Manager of Drug Information

Vizient Center for Pharmacy Practice Excellence

Host:

Stacy Lauderdale, PharmD, BCPS

Associate Vice President

Vizient Center for Pharmacy Practice Excellence

Show Notes:

[01:38-05:32] What changed in the recent CDC update for healthy children

[05:33-09:32] Discussion of COVID-19 outcomes and vaccination in children

[09:33-11:47] Specific risk factors for pediatric patients

[11:48-12:47] Is the US an outlier for not universally recommending the COVID-19 vaccine for healthy children and making no recommendation in healthy pregnant women?

[12:48-14:03] The FDA’s proposed regulatory framework for COVID-19 vaccine approval

[14:04-15:18] FDA’s approach to implementing revised requirements for randomized controlled trials

[15:19-16:57] Key discussion points from the May meeting of the Vaccines and Related Biological Products Advisory Committee

[17:00-18:27] Topics requiring further clarification about COVID-19 vaccine

Links | Resources:

Vizient resources:

• Minute Market Insight: Potential ACIP COVID-19 recommendation changes April 2025: https://www.vizientinc.com/download?342668
• Minute Market Insight: May 2025 COVID-19 vaccine recommendation and policy updates: https://www.vizientinc.com/download?352336

Additional resources:

• FDA perspective piece published in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMsb2506929
• ACIP meeting information: https://www.cdc.gov/acip/meetings/index.html
• CDC childhood immunization schedule: https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html
• CDC adult immunization schedule by medical condition: https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html
• CDC RESP-NET: https://www.cdc.gov/resp-net/dashboard/
• WHO COVID-19 dashboard: https://data.who.int/dashboards/covid19/deaths
• MMWR - COVID-19–Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months: https://www.cdc.gov/mmwr/volumes/73/wr/mm7338a1.htm?utm_source=chatgpt.com
• MMWR – MIS-C, US 2023: https://www.cdc.gov/mmwr/volumes/73/wr/mm7310a2.htm

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed

Pharmacy reverse distributors play a key role in making pharmaceutical returns more efficient, helping with processing, financial settlements and delivering helpful data. They're in a unique spot to support efforts to prevent diversion, speed up inventory returns, and even contribute to sustainability goals. Kyle Hoelting, director of pharmacy supply assurance and stewardship at Vizient, along with Paige Ivey, senior national accounts director, and Houston Blankinship, senior director of customer experience for healthcare product operations at Inmar Intelligence join host Carolyn Liptak, pharmacy executive director in Vizient Center for Pharmacy Practice Excellence and host for today's conversation.

Guest speakers:

Kyle Hoelting, Pharm.D, BCPS Director, Pharmacy Supply Assurance & Stewardship Vizient Center for Pharmacy Practice Excellence

Paige Ivey Senior National Accounts Director Inmar Intelligence

Houston Blankenship Senior Director of Customer Experience for Healthcare Product Operations Inmar Intelligence

Host: Carolyn Liptak, MBA, RPh Pharmacy Executive Director Vizient

Show Notes:

[01:05-03:33] Background for Kyle, Paige, Houston [03:34-05:10] How the pharmaceutical supply chain works and how everything is interconnected [05:10-09:32] How reverse distribution specifically supports pharmacy operations [09:33-11:16] How data that comes from reverse distribution can offer some great insights for pharmacy leaders [11:58-13:57] How data that comes from reverse distribution can give insight to drug shortages [13:58-16:42] Inmar's role with insight into drug shortages [16:43-21:05] Go-to resources for those wanting to explore more on stewardship and protective purchases

Links | Resources:

Drug shortage stewardship: A novel solution for an old problem

Vizient Essential Medications List

Vizient Key performance indicators for the management of drug shortages

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed

Recently, there has been a lot of interest generated by a new FDA approval. Suzetrigine (Journavx) was recently approved by the US Food and Drug Administration for the management of pain. Although there is a lot of excitement about having a new tool in the toolbox, there are certain limitations that are important to consider. In this episode of Verified Rx, Dave Peterson, pharmacist and drug information specialist for the University of Utah Health joins us to discuss this exciting new non opioid medication.

Guest speaker:

Dave Peterson, PharmD, BCPS

Drug Information Specialist

University of Utah Drug Information Service

Host:

Kerry Schwarz, PharmD, MPH

Senior Clinical Manager, Evidence-Based Medicine and Outcomes

Center for Pharmacy Practice Excellence (CPPE)

Show Notes:

[00:54-02:24] Information about Suzetrigine

[02:25-04:06] What distinguishes suzetrigine from other non-opioid analgesics

[04:07-05:09] What suzetrigine is indicated for

[05:10-06:14] How suzetrigine is being studied

[06:15-08:40] Surgical models and the endpoints that we commonly see in these studies

[08:41-10:25] Making sense of discordant study results

[10:26-12:02] Moving beyond the evidence to real world utilization of suzetrigine

[12:03-14:03] How cost factors into real-world utilization

[14:04-16:21] What Dave is keeping his eye on in terms of clinical concerns

[16:22-17:28] What Dave is excited about with the advent of suzetrigine

Links | Resources:

No pain, much gain?

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed